528 related articles for article (PubMed ID: 23169778)
41. Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim.
Kuter DJ; Macahilig C; Grotzinger KM; Poston SA; Wang PF; Dawson KL; Ward M
Int J Hematol; 2015 Mar; 101(3):255-63. PubMed ID: 25586660
[TBL] [Abstract][Full Text] [Related]
42. [Retrospective analysis of eltrombopag for the treatment of refractory primary immune thrombocytopenia in Japan].
Yoshida M; Kanashima H; Nakao T; Ogawa Y; Hino M; Nakane T; Ohta T; Kumura T; Manabe M; Yamamura R; Yamane T
Rinsho Ketsueki; 2013 May; 54(5):444-50. PubMed ID: 23727682
[TBL] [Abstract][Full Text] [Related]
43. Eltrombopag for the Treatment of Immune Thrombocytopenia: The Aegean Region of Turkey Experience.
Özdemirkıran F; Payzın B; Kiper HD; Kabukçu S; Akgün Çağlıyan G; Kahraman S; Sevindik ÖG; Ceylan C; Kadıköylü G; Şahin F; Keskin A; Arslan Ö; Özcan MA; Kabukçu G; Görgün G; Bolaman Z; Büyükkeçeci F; Bilgir O; Alacacıoğlu İ; Vural F; Tombuloğlu M; Gökgöz Z; Saydam G
Turk J Haematol; 2015 Dec; 32(4):323-8. PubMed ID: 25914025
[TBL] [Abstract][Full Text] [Related]
44. Eltrombopag named patient programme for patients with chronic immune thrombocytopenia.
Scully M; Kaczmarski R; Myers B; Collins R; Emohare O; Bolton-Maggs PH
Br J Haematol; 2012 Apr; 157(2):259-60. PubMed ID: 22091659
[No Abstract] [Full Text] [Related]
45. No cross-resistance after sequential use of romiplostim and eltrombopag in chronic immune thrombocytopenic purpura.
D'Arena G; Guariglia R; Mansueto G; Martorelli MC; Pietrantuono G; Villani O; Lerose R; Musto P
Blood; 2013 Feb; 121(7):1240-2. PubMed ID: 23411736
[No Abstract] [Full Text] [Related]
46. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.
Mittelman M; Platzbecker U; Afanasyev B; Grosicki S; Wong RSM; Anagnostopoulos A; Brenner B; Denzlinger C; Rossi G; Nagler A; Garcia-Delgado R; Portella MSO; Zhu Z; Selleslag D
Lancet Haematol; 2018 Jan; 5(1):e34-e43. PubMed ID: 29241762
[TBL] [Abstract][Full Text] [Related]
47. Health-related quality of life in children with chronic immune thrombocytopenia treated with eltrombopag in the PETIT study.
Grainger JD; Blanchette VS; Grotzinger KM; Roy A; Bussel JB
Br J Haematol; 2019 Apr; 185(1):102-106. PubMed ID: 30592022
[TBL] [Abstract][Full Text] [Related]
48. Safety and Efficacy of Eltrombopag in Children and Adults with Immune Thrombocytopenia: A Systematic Review and Meta-Analysis.
Kolanis S; Vasileiou E; Hatzipantelis E; Economou M; Tragiannidis A
Cardiovasc Hematol Agents Med Chem; 2021; 19(1):83-92. PubMed ID: 32914722
[TBL] [Abstract][Full Text] [Related]
49. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia.
Afdhal NH; Giannini EG; Tayyab G; Mohsin A; Lee JW; Andriulli A; Jeffers L; McHutchison J; Chen PJ; Han KH; Campbell F; Hyde D; Brainsky A; Theodore D;
N Engl J Med; 2012 Aug; 367(8):716-24. PubMed ID: 22913681
[TBL] [Abstract][Full Text] [Related]
50. Spotlight on eltrombopag in pediatric ITP in China: a long-term observational study in real-world practice.
Cheng X; Fu L; Ma J; Gu H; Chen Z; Zhao L; Wang X; Wu R
Blood Adv; 2021 Oct; 5(19):3799-3806. PubMed ID: 34605871
[TBL] [Abstract][Full Text] [Related]
51. Thrombopoietin receptor agonist switch in children with persistent and chronic severe immune thrombocytopenia: A retrospective analysis in a large tertiary center.
Suntsova EV; Maschan AA; Baydildina DD; Kalinina II; Petrova UN; Pshonkin AV; Novichkova GA
Pediatr Blood Cancer; 2019 Jun; 66(6):e27704. PubMed ID: 30854783
[TBL] [Abstract][Full Text] [Related]
52. Eltrombopag for chronic immune thrombocytopenia.
Tanimoto T; Fukunaga S; Hori A; Yagasaki F; Ono S
Lancet; 2011 Jun; 377(9781):1919; author reply 1919-20. PubMed ID: 21641478
[No Abstract] [Full Text] [Related]
53. Modeling and Simulation Support Eltrombopag Dosing in Pediatric Patients With Immune Thrombocytopenia.
Wire MB; Li X; Zhang J; Sallas W; Aslanis V; Ouatas T
Clin Pharmacol Ther; 2018 Dec; 104(6):1199-1207. PubMed ID: 29536526
[TBL] [Abstract][Full Text] [Related]
54. Eltrombopag: an oral thrombopoietin receptor agonist for the treatment of idiopathic thrombocytopenic purpura.
Zhang Y; Kolesar JM
Clin Ther; 2011 Nov; 33(11):1560-76. PubMed ID: 22054810
[TBL] [Abstract][Full Text] [Related]
55. Clinical pharmacokinetics, platelet response, and safety of eltrombopag at supratherapeutic doses of up to 200 mg once daily in healthy volunteers.
Matthys G; Park JW; McGuire S; Wire MB; Bowen C; Williams D; Jenkins J; Peng B
J Clin Pharmacol; 2011 Mar; 51(3):301-8. PubMed ID: 20418510
[TBL] [Abstract][Full Text] [Related]
56. Successful eltrombopag treatment of severe refractory thrombocytopenia in chronic myelomonocytic leukemia: Two cases reports: A CARE-compliant article.
Gao Y; Gong M; Zhang C; Kong X; Ma Y
Medicine (Baltimore); 2017 Oct; 96(43):e8337. PubMed ID: 29069007
[TBL] [Abstract][Full Text] [Related]
57. Sudden blindness due to bilateral central retinal artery occlusion in a patient on eltrombopag.
Au WY; Ma ES; Chow PC; Kan YT
Ann Hematol; 2014 May; 93(5):881-2. PubMed ID: 24048635
[No Abstract] [Full Text] [Related]
58. [Efficacy and safety of eltrombopag in the treatment of primary immune thrombocytopenia: real-world data from a single medical center].
Dong XF; Li YL; Li NB; Lin WN; Wang T; Wang HQ; Li LJ; Qu W; Xing LM; Liu H; Wu YH; Wang GJ; Song J; Guan J; Wang XM; Shao ZH; Fu R
Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):271-276. PubMed ID: 38716599
[No Abstract] [Full Text] [Related]
59. Infection-related transient loss of response and other early side effects in chronic ITP during treatment with thrombopoietin mimetics.
Meyer O; Salama A
Onkologie; 2011; 34(1-2):10-3. PubMed ID: 21346379
[TBL] [Abstract][Full Text] [Related]
60. Efficacy and safety of eltrombopag in treatment-refractory primary immune thrombocytopenia: a retrospective study.
Eser A; Toptas T; Kara O; Sezgin A; Noyan-Atalay F; Yilmaz G; Ozgumus T; Pepedil-Tanrikulu F; Kaygusuz-Atagunduz I; Firatli-Tuglular T
Blood Coagul Fibrinolysis; 2016 Jan; 27(1):47-52. PubMed ID: 26258668
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
